Table 2
(a) CDC- and AMS-ELISA-based pretransplant crossmatch results of the 43-year-old recipient with her completely HLA-matched cadaveric kidney donor. (b) Corresponding analyses for anti-HLA antibody screening/identification.
| (a) |
| | Serum sample | CDC-CM (#) | AMS-ELISA-CM | | PBL | T-cell | B-cell | Class I | Class II |
| | 10/2009 | 6 | 6 | 8 | neg. | neg. | | 10/2010 | 6/8 | 6 | 8 | neg. | neg. |
|
|
neg.: negative; pos.: positive; #: NIH score system of the standard CDC-based crossmatch as a percent of positive/dead (red coloured) cells (%) as shown in Table 1(a).
|
| (b) |
| | Serum sample | Screening ELISA/DynaChip (Ø) | CDC cell tray (PBL) | | Class I | Class II | Class I / II |
| | 07/2009 | neg. (Ø) | neg. (Ø) | n.d. | | 10/2009 | neg. (Ø) | neg. (Ø) | pos. (68% PRA) | | 01/2010 | neg. | neg. | n.d. | | 04/2010 | neg. | neg. | n.d. | | 07/2010 | neg. | neg. | n.d. | | 10/2010 | neg. (Ø) | neg. (Ø) | pos. (61% PRA) |
|
|
neg.: negative; pos.: positive; n.d.: not done; the CDC-based cell tray analysis was performed during the autumnal screening (i.e., once a year in accordance with the guidelines of the European Federation of Immunogenetics (EFI)) using the samples taken in October 2009 and October 2010; Ø: additionally performed DynaChip analyses in all cases exhibiting negative results in accordance with the screening ELISA.
|
